Bill Lundberg

Chief Scientific Officer
Pharmaceuticals
CRISPR Therapeutics
Switzerland

Biography

Dr. Bill Lundberg has extensive experience across all aspects and phases of drug development in both academic and industry settings. He was previously Vice President and Head of Translational Medicine at Alexion Pharmaceuticals, where he was responsible for all R&D from discovery to clinical proof-of-concept. Before that, Bill held senior positions at Taligen Therapeutics, Antisoma, Xanthus (acquired by Antisoma), Wyeth (now Pfizer) and Genzyme, overseeing the development of diverse portfolios. Bill received his B.S. in biology from the Massachusetts Institute of Technology (MIT), M.D. from Stanford Medical School and M.B.A. from the University of Massachusetts Amherst. As a post-doctoral fellow he studied at the Whitehead Institute at MIT, and trained in internal medicine and oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute.

Research Intrest

Pharmaceutical Sciences

Global Scientific Words in Pharmaceutical Sciences